Essential Insights
- USC researchers developed a scalable method for immune cell precursor production.
- Granulocyte-monocyte progenitors (GMPs) can self-renew and generate functional immune cells.
- Engineered GMPs showed potential in treating cancer and immune deficiencies.
- Off-the-shelf therapies could be created using genetically modified GMPs.
Unlocking Potential in Cancer Treatment
Scientists at USC Stem Cell have made a groundbreaking advancement in cancer immunotherapy. They have developed a method to create a renewable supply of granulocyte-monocyte progenitors (GMPs). These are progenitor cells that give rise to macrophages, crucial players in the immune system’s fight against infections and now, increasingly, cancer. This new technique not only allows scientists to expand GMPs in the lab but also enables genetic modifications that enhance their cancer-fighting capabilities.
Macrophages naturally infiltrate tumors, consuming cancer cells and orchestrating immune responses. While T-cell therapies have gained traction, GMP-derived macrophages could offer significant advantages, especially in treating solid tumors. Traditional mature macrophages face hurdles: they are challenging to cultivate, difficult to engineer, and tend to accumulate in unintended organs. By focusing on GMPs earlier in their development, researchers have found a way to sidestep these issues. They used a carefully curated chemical cocktail to keep GMPs in a state suitable for expansion, preserving their ability to generate functional immune cells.
A New Strategy for Broader Applications
This study highlights another significant finding: GMPs can self-renew, a feature typically linked to stem cells. This allows them to divide and maintain their identity, creating a sustainable source for therapies targeting cancer and potentially other conditions. Researchers equipped GMPs with chimeric antigen receptors (CAR) to help them recognize cancer cells. They also integrated signals to activate nearby immune cells, boosting the overall immune response. This could lead to off-the-shelf therapies, available for multiple patients without requiring custom treatments.
Researchers tested GMPs in mice with various cancers, observing that engineered GMPs significantly slowed disease progression. They successfully settled into bone marrow and consistently generated engineered macrophages. This continuous supply helps prevent the rapid cell loss that hampers traditional macrophage therapies. Excitingly, the potential of this platform extends beyond oncology. Initial studies show that GMP treatments can also restore immune function in models of chronic granulomatous disease, hinting at broader applications in immune deficiencies.
This work offers a hopeful outlook for cancer treatment and other immune disorders. By refining the stages of cell development used in therapies, researchers can enhance the effectiveness of immunotherapy. GMPs represent a promising avenue to provide effective, scalable, and adaptable cell-based treatments, paving the way for the next generation of immunotherapy.
Continue Your Tech Journey
Learn how the Internet of Things (IoT) is transforming everyday life.
Explore past and present digital transformations on the Internet Archive.
TechV1
